http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 11 Sep 2026 08:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Sep+11/27050992.html si-local-file:///var/storage/secattach/20260911/27050992.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Sep+11/27050992.html Fri, 11 Sep 2026 08:31:00 -0400 BIAF http://www.streetinsider.com/Press+Releases/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html <p>DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: <strong>NeOnc Technologies Holdings (NASDAQ:NTHI)</strong> is pairing fresh institutional capital with encouraging NEO100 clinical data; <strong>Opus Genetics (NASDAQ:IRD)</strong> is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; <strong>bioAffinity Technologies (NASDAQ:BIAF)</strong> removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; <strong>Tenon Medical (NASDAQ:TNON)</strong> eliminated roughly $5.16 million of convertible-note obligations ahead of maturity.</p> <p><strong>NeOnc Raises $15 Million At Market, Adding Fuel to Strong NEO100 Data</strong></p> http://www.streetinsider.com/Press+Releases/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html Wed, 09 Sep 2026 11:55:26 -0400 BIAF IRD NTHI TNON http://www.streetinsider.com/Press+Releases/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html <p>DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: <strong>NeOnc Technologies Holdings (NASDAQ:NTHI)</strong> is pairing fresh institutional capital with encouraging NEO100 clinical data; <strong>Opus Genetics (NASDAQ:IRD)</strong> is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; <strong>bioAffinity Technologies (NASDAQ:BIAF)</strong> removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; <strong>Tenon Medical (NASDAQ:TNON)</strong> eliminated roughly $5.16 million of convertible-note obligations ahead of maturity.</p> <p><strong>NeOnc Raises $15 Million At Market, Adding Fuel to Strong NEO100 Data</strong></p> http://www.streetinsider.com/Press+Releases/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html Wed, 09 Sep 2026 11:55:26 -0400 BIAF IRD NTHI TNON http://www.streetinsider.com/Press+Releases/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html <p>DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: <strong>NeOnc Technologies Holdings (NASDAQ:NTHI)</strong> is pairing fresh institutional capital with encouraging NEO100 clinical data; <strong>Opus Genetics (NASDAQ:IRD)</strong> is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; <strong>bioAffinity Technologies (NASDAQ:BIAF)</strong> removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; <strong>Tenon Medical (NASDAQ:TNON)</strong> eliminated roughly $5.16 million of convertible-note obligations ahead of maturity.</p> <p><strong>NeOnc Raises $15 Million At Market, Adding Fuel to Strong NEO100 Data</strong></p> http://www.streetinsider.com/Press+Releases/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html Wed, 09 Sep 2026 11:55:26 -0400 BIAF IRD NTHI TNON http://www.streetinsider.com/Press+Releases/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html <p>DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: <strong>NeOnc Technologies Holdings (NASDAQ:NTHI)</strong> is pairing fresh institutional capital with encouraging NEO100 clinical data; <strong>Opus Genetics (NASDAQ:IRD)</strong> is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; <strong>bioAffinity Technologies (NASDAQ:BIAF)</strong> removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; <strong>Tenon Medical (NASDAQ:TNON)</strong> eliminated roughly $5.16 million of convertible-note obligations ahead of maturity.</p> <p><strong>NeOnc Raises $15 Million At Market, Adding Fuel to Strong NEO100 Data</strong></p> http://www.streetinsider.com/Press+Releases/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html Wed, 09 Sep 2026 11:55:26 -0400 BIAF IRD NTHI TNON http://www.streetinsider.com/Globe+Newswire/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html <p>DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: <strong>NeOnc Technologies Holdings (NASDAQ:NTHI)</strong> is pairing fresh institutional capital with encouraging NEO100 clinical data; <strong>Opus Genetics (NASDAQ:IRD)</strong> is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; <strong>bioAffinity Technologies (NASDAQ:BIAF)</strong> removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; <strong>Tenon Medical (NASDAQ:TNON)</strong> eliminated roughly $5.16 million of convertible-note obligations ahead of maturity.</p> <p><strong>NeOnc Raises $15 Million At Market, Adding Fuel to Strong NEO100 Data</strong></p> http://www.streetinsider.com/Globe+Newswire/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html Wed, 09 Sep 2026 11:55:26 -0400 BIAF IRD NTHI TNON http://www.streetinsider.com/Globe+Newswire/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html <p>DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: <strong>NeOnc Technologies Holdings (NASDAQ:NTHI)</strong> is pairing fresh institutional capital with encouraging NEO100 clinical data; <strong>Opus Genetics (NASDAQ:IRD)</strong> is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; <strong>bioAffinity Technologies (NASDAQ:BIAF)</strong> removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; <strong>Tenon Medical (NASDAQ:TNON)</strong> eliminated roughly $5.16 million of convertible-note obligations ahead of maturity.</p> <p><strong>NeOnc Raises $15 Million At Market, Adding Fuel to Strong NEO100 Data</strong></p> http://www.streetinsider.com/Globe+Newswire/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html Wed, 09 Sep 2026 11:55:26 -0400 BIAF IRD NTHI TNON http://www.streetinsider.com/Globe+Newswire/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html <p>DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: <strong>NeOnc Technologies Holdings (NASDAQ:NTHI)</strong> is pairing fresh institutional capital with encouraging NEO100 clinical data; <strong>Opus Genetics (NASDAQ:IRD)</strong> is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; <strong>bioAffinity Technologies (NASDAQ:BIAF)</strong> removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; <strong>Tenon Medical (NASDAQ:TNON)</strong> eliminated roughly $5.16 million of convertible-note obligations ahead of maturity.</p> <p><strong>NeOnc Raises $15 Million At Market, Adding Fuel to Strong NEO100 Data</strong></p> http://www.streetinsider.com/Globe+Newswire/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html Wed, 09 Sep 2026 11:55:26 -0400 BIAF IRD NTHI TNON http://www.streetinsider.com/Globe+Newswire/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html <p>DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: <strong>NeOnc Technologies Holdings (NASDAQ:NTHI)</strong> is pairing fresh institutional capital with encouraging NEO100 clinical data; <strong>Opus Genetics (NASDAQ:IRD)</strong> is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; <strong>bioAffinity Technologies (NASDAQ:BIAF)</strong> removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; <strong>Tenon Medical (NASDAQ:TNON)</strong> eliminated roughly $5.16 million of convertible-note obligations ahead of maturity.</p> <p><strong>NeOnc Raises $15 Million At Market, Adding Fuel to Strong NEO100 Data</strong></p> http://www.streetinsider.com/Globe+Newswire/Four+Biotech+Stories+Heating+Up+Right+Now/27041460.html Wed, 09 Sep 2026 11:55:26 -0400 BIAF IRD NTHI TNON http://www.streetinsider.com/Corporate+News/BioAffinity+regains+Nasdaq+compliance+for+stock+and+warrants/27039764.html <p>BioAffinity Technologies (NASDAQ: BIAF, BIAFW) announced it has received written notice from the Nasdaq Stock Market LLC confirming the company has regained compliance with Nasdaq's applicable listing requirements.</p><p>In a letter dated September 8, 2026, Nasdaq confirmed that the company has satisfied Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, and Listing Rule 5560(a), which establishes listing requirements applicable to rights and warrants. A previously scheduled hearing before the Nasdaq Hearings Panel has been cancelled as a result.</p><p>The company's common stock and warrants will continue to be listed and traded on the Nasdaq Capital Market under http://www.streetinsider.com/Corporate+News/BioAffinity+regains+Nasdaq+compliance+for+stock+and+warrants/27039764.html Wed, 09 Sep 2026 08:08:57 -0400 BIAF http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++bioAffinity+Technologies+++++++++++++/26990512.html si-local-file:///var/storage/secattach/20260827/26990512.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++bioAffinity+Technologies+++++++++++++/26990512.html Thu, 27 Aug 2026 16:31:00 -0400 BIAF O.22213627 http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++bioAffinity+Technologies+++++++++++++/26990512.html si-local-file:///var/storage/secattach/20260827/26990512.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++bioAffinity+Technologies+++++++++++++/26990512.html Thu, 27 Aug 2026 16:31:00 -0400 BIAF O.22213627 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Aug+20/26953501.html si-local-file:///var/storage/secattach/20260820/26953501.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Aug+20/26953501.html Thu, 20 Aug 2026 08:31:00 -0400 BIAF O.22213627 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Aug+20/26953501.html si-local-file:///var/storage/secattach/20260820/26953501.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Aug+20/26953501.html Thu, 20 Aug 2026 08:31:00 -0400 BIAF O.22213627 http://www.streetinsider.com/Stock+Splits/bioAffinity+Technologies+sets+1-for-15+reverse+stock+split+Aug.+24/26953150.html <p>bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) announced a 1-for-15 reverse split of its common stock, effective at the open of trading on the Nasdaq Capital Market on August 24, 2026.</p> <p>The reverse stock split was approved by stockholders at the company's annual meeting on April 30, 2026. The split is primarily intended to bring the company into compliance with Nasdaq's minimum bid price requirement.</p> <p>Following the split, every 15 shares of issued and outstanding common stock will be exchanged for one share. The company will have approximately 592,373 shares of common stock issued and outstanding after the split takes effect. Stockholders who http://www.streetinsider.com/Stock+Splits/bioAffinity+Technologies+sets+1-for-15+reverse+stock+split+Aug.+24/26953150.html Thu, 20 Aug 2026 08:00:23 -0400 BIAF BIAFW O.22213627 http://www.streetinsider.com/Stock+Splits/bioAffinity+Technologies+sets+1-for-15+reverse+stock+split+Aug.+24/26953150.html <p>bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) announced a 1-for-15 reverse split of its common stock, effective at the open of trading on the Nasdaq Capital Market on August 24, 2026.</p> <p>The reverse stock split was approved by stockholders at the company's annual meeting on April 30, 2026. The split is primarily intended to bring the company into compliance with Nasdaq's minimum bid price requirement.</p> <p>Following the split, every 15 shares of issued and outstanding common stock will be exchanged for one share. The company will have approximately 592,373 shares of common stock issued and outstanding after the split takes effect. Stockholders who http://www.streetinsider.com/Stock+Splits/bioAffinity+Technologies+sets+1-for-15+reverse+stock+split+Aug.+24/26953150.html Thu, 20 Aug 2026 08:00:23 -0400 BIAF BIAFW O.22213627 http://www.streetinsider.com/Stock+Splits/bioAffinity+Technologies+sets+1-for-15+reverse+stock+split+Aug.+24/26953150.html <p>bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) announced a 1-for-15 reverse split of its common stock, effective at the open of trading on the Nasdaq Capital Market on August 24, 2026.</p> <p>The reverse stock split was approved by stockholders at the company's annual meeting on April 30, 2026. The split is primarily intended to bring the company into compliance with Nasdaq's minimum bid price requirement.</p> <p>Following the split, every 15 shares of issued and outstanding common stock will be exchanged for one share. The company will have approximately 592,373 shares of common stock issued and outstanding after the split takes effect. Stockholders who http://www.streetinsider.com/Stock+Splits/bioAffinity+Technologies+sets+1-for-15+reverse+stock+split+Aug.+24/26953150.html Thu, 20 Aug 2026 08:00:23 -0400 BIAF BIAFW O.22213627 http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54592176&amp;newsitemid=20260820312539&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=77e35d95ffb20408325e8edc15f553be" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (NASDAQ: BIAF, BIAFW)</b>, a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24, 2026, the Company’s common stock will trade on a post-split basis under the symbol BIAF. The reverse stock split was approved by the Company’s stockholders at the Company’s annual meeting held on April 30, 2026. </p><p> As a result of the reverse http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html Thu, 20 Aug 2026 08:00:00 -0400 BIAF BIAFW O.22213627 http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54592176&amp;newsitemid=20260820312539&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=77e35d95ffb20408325e8edc15f553be" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (NASDAQ: BIAF, BIAFW)</b>, a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24, 2026, the Company’s common stock will trade on a post-split basis under the symbol BIAF. The reverse stock split was approved by the Company’s stockholders at the Company’s annual meeting held on April 30, 2026. </p><p> As a result of the reverse http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html Thu, 20 Aug 2026 08:00:00 -0400 BIAF BIAFW O.22213627 http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54592176&amp;newsitemid=20260820312539&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=77e35d95ffb20408325e8edc15f553be" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (NASDAQ: BIAF, BIAFW)</b>, a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24, 2026, the Company’s common stock will trade on a post-split basis under the symbol BIAF. The reverse stock split was approved by the Company’s stockholders at the Company’s annual meeting held on April 30, 2026. </p><p> As a result of the reverse http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html Thu, 20 Aug 2026 08:00:00 -0400 BIAF BIAFW O.22213627 http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54592176&amp;newsitemid=20260820312539&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=77e35d95ffb20408325e8edc15f553be" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (NASDAQ: BIAF, BIAFW)</b>, a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24, 2026, the Company’s common stock will trade on a post-split basis under the symbol BIAF. The reverse stock split was approved by the Company’s stockholders at the Company’s annual meeting held on April 30, 2026. </p><p> As a result of the reverse http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html Thu, 20 Aug 2026 08:00:00 -0400 BIAF BIAFW O.22213627 http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54592176&amp;newsitemid=20260820312539&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=77e35d95ffb20408325e8edc15f553be" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (NASDAQ: BIAF, BIAFW)</b>, a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24, 2026, the Company’s common stock will trade on a post-split basis under the symbol BIAF. The reverse stock split was approved by the Company’s stockholders at the Company’s annual meeting held on April 30, 2026. </p><p> As a result of the reverse http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html Thu, 20 Aug 2026 08:00:00 -0400 BIAF BIAFW O.22213627 http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54592176&amp;newsitemid=20260820312539&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=77e35d95ffb20408325e8edc15f553be" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (NASDAQ: BIAF, BIAFW)</b>, a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24, 2026, the Company’s common stock will trade on a post-split basis under the symbol BIAF. The reverse stock split was approved by the Company’s stockholders at the Company’s annual meeting held on April 30, 2026. </p><p> As a result of the reverse http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Announces+1-for-15+Reverse+Stock+Split+Effective+at+the+Open+of+Trading+on+August+24%2C+2026/26953120.html Thu, 20 Aug 2026 08:00:00 -0400 BIAF BIAFW O.22213627 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Aug+18/26941133.html si-local-file:///var/storage/secattach/20260818/26941133.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Aug+18/26941133.html Tue, 18 Aug 2026 08:31:00 -0400 BIAF O.22213627 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Aug+18/26941133.html si-local-file:///var/storage/secattach/20260818/26941133.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Aug+18/26941133.html Tue, 18 Aug 2026 08:31:00 -0400 BIAF O.22213627